slidedeck.co

Theranos, Inc. presentation, December 2010 board meeting

Cover slide of the Theranos, Inc. 2010 presentation
Cover of Theranos, Inc.'s 2010 presentation.

This internal Theranos board of directors deck, dated December 7, 2010, was produced as a court exhibit. It opens with a cover slide and an agenda running from a light breakfast through administrative items, products, commercial, organization, legal, finance and a closing discussion. The administrative section covers approvals and director matters, including warrant approval, minutes, a director search process and compensation review. The 2010 goals recap sets targets for launching Theranos Systems 4.0, reaching volume capacity and signing commercial deals. The products section pairs a row of instrument photographs with a validation grid of charts for technologies such as centrifugation, nucleic acid amplification, cytometry, colorimetry, ELISA and robotics. The commercial section presents a 2011 quarterly plan and lists retail, pharmaceutical and provider partners by logo text. The organization slide describes restructuring and hiring targets, the legal slide lists a patent portfolio table with codes and status, and the finance slide covers real estate and financing items. Built largely from dense bullet text and tables in a consistent green template, each slide is marked confidential in its footer.

Slides worth studying

  • Slide 9: Places a chart beside each technology photo so the validation data carries the point of the slide.
  • Slide 21: Uses a structured table with code, patent family, status and value columns to make a dense legal portfolio easy to scan.

Questions about this deck

How many slides does the Theranos, Inc. board of directors deck dated December 7, 2010 have?

The deck has 22 pages. Slide 3 is the title slide for the Meeting of the Board of Directors on December 7, 2010, from 8:15 a.m. to 11:45 a.m.

How is the agenda of the Theranos, Inc. board meeting structured?

Slide 4 lists a light breakfast from 8:15 to 8:30 a.m., followed by Administrative, Products, Commercial, Organization, Legal, Finance, and Discussion and close of meeting, which runs until 11:45 a.m. Each section has its own time range on the slide.

What does the Theranos, Inc. deck say about its 2011 commercial plan?

Slide 15 lays out the 2011 Commercial Plan by quarter. Q1 is to prepare for retail and physician's office pilot launch, Q2 to initiate those pilots, Q3 to begin the rollout, and Q4 to scale rollouts and begin deployments with multiple retail partners.

What does the Theranos, Inc. deck say about hiring and headcount?

Slide 19 says the company is hiring to continually double headcount, with a target of 150 people by 3/31/11. The same slide states that 13 team leads are in place company wide.

Details

More from Theranos

All Theranos decks in the library

Review score: 5 out of 10, Needs substantial work

Presentation quality, judged with the SlideDeck Co review heuristic. Ask, evidence and idea merit are not rated here.

This is a board meeting deck that follows its agenda in order (slide 4 agenda, then administrative, products, commercial, organization, legal and finance), so the route is easy to follow and the template is consistent. Most content slides are sparse, unemphasized green bullet lists with no hierarchy, such as slides 14 to 18 and 22, which are lists of names or topics with no numbers, takeaways or visuals. The few visual pages work: slide 9 labels six instrument photos clearly and slide 21 gives a readable patent table, but the validation chart grid (slide 11) has clipped axis text and tiny unreadable plots, and slide 15 has text crowding the footer. Without a presenter, the audience cannot tell what is being decided or why from many of the pages.

Worth keeping: Keep the consistent green template, the timed agenda on slide 4, the labeled photo grid on slide 9 and the structured patent table on slide 21.

Most useful repair: Add a takeaway or decision framing to the list slides, fix the clipped axis label on slide 11 and the overflow on slide 15, and enlarge or annotate the validation charts.

What would change the score: I would replace bare name lists on slides 14 to 18 and 22 with figures, timelines or status markers and give titles that state the point.

Confidence medium. 22 of 22 pages inspected on contact sheets, 3 at readable size. Reviewed 2026-11-09. Model-assisted review (claude-sonnet-5-5).

Full text of the slides (22 slides)

Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.

Slide 1

15046

Message

From: Elizabeth Holmes [/O=THERANOS ORGANIZATION/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=EHOLMES]

Sent: 12/7/2010 2:11:01 PM

To: Sunny Balwani [[email protected]]

Elizabeth Holmes

President and CEO

Theranos, Inc.

Tel: 650.470.6111

Fax: 650.838.9804

=========================================

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT -- This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 3200 Hillview Avenue, Palo Alto, CA, 94304

650-838-9292 www.theranos.com

=========================================

FOIA Confidential Treatment Requested by Theranos

TS-0967741

Visuals: A full-page scan of a printed email message on white paper, with black text and one thick black horizontal rule under the word Message. No photographs, charts, logos or icons. The scan is full-bleed across the whole slide with slight grey scanning texture and no framing, cropping or overlay.

Slide 2

File Produced in Native Format

FOIA Confidential Treatment Requested by Theranos

TS-0967742

Slide 3

Meeting of the Board of Directors

December 7, 2010

8:15 a.m. – 11:45 a.m.

Theranos, Inc.

This presentation and its contents are Theranos proprietary and confidential

Visuals: Logo: the theranos corporate logo at top left (image 232 by 63 pixels, placed at x 2.7%, y 3.5%, w 24.2%, h 8.8%). It shows a green faceted diamond mark with a white four-point cross-shaped centre, a grey italic lowercase wordmark 'theranos' to its right, and a small grey italic tagline 'redefining healthcare' beneath the wordmark, left-aligned to the wordmark. No photographs, charts, tables or other illustrations.

Slide 4

theranos

redefining healthcare

Agenda

Light breakfast

8:15 – 8:30

Administrative

8:30 – 9:00

Products

9:00 – 9:30

Commercial

9:30 – 10:10

Organization

10:10 – 10:40

Legal

10:40 – 10:55

Finance

10:55 – 11:15

Discussion and close of

meeting

11:15 – 11:45

Theranos Confidential

2

Visuals: A table with two columns and eight rows and no header row. Column 1 holds activity names and column 2 holds time ranges. Row 1: Light breakfast | 8:15 – 8:30. Row 2: Administrative | 8:30 – 9:00. Row 3: Products | 9:00 – 9:30. Row 4: Commercial | 9:30 – 10:10. Row 5: Organization | 10:10 – 10:40. Row 6: Legal | 10:40 – 10:55. Row 7: Finance | 10:55 – 11:15. Row 8: Discussion and close of meeting | 11:15 – 11:45. Cell fills alternate in tints of teal: row 1 #BBE0E3, rows 2, 3, 6 and 8 #E7F3F4 (row 8 is taller at 10.4%), rows 4, 5 and 7 #F3F9FA, separated by thin white gutters. The theranos logo is a raster image of 232 by 63 pixels: a green (#00875A-like) faceted diamond emblem at left, with the italic grey wordmark 'theranos' in grey (#6D6E71-like) and the small grey tagline 'redefining healthcare' beneath it. No photographs, charts or other graphics.

Slide 5

theranos / redefining healthcare / Administrative / Approval of updated BCBSVP warrant / Approval of prior minutes / • Meeting of the Board of Directors – Tuesday, August 10th, 2010 / Approval of Channing Robertson agreement structure / Acceptance of Pete Thomas resignation / Approval of Pete Thomas strategic advisory agreement terms / Theranos Confidential / 3

Visuals: One raster image: the Theranos logo at top left, box x 2.7%, y 3.5%, 24.2% wide by 8.8% high (232 by 63 pixels). It shows a green faceted diamond-shaped emblem with a white four-point cross-cut centre, to the left of the lowercase grey italic wordmark 'theranos' and the small grey italic tagline 'redefining healthcare' beneath it. The emblem's dominant colours are green gradients (#008851 to lighter mint) with grey #6A737B wordmark text. The logo is not cropped and has no overlay. No other visual elements are present.

Slide 6

Administrative

Theranos logo: theranos redefining healthcare

Approval of new director search process

Review of new candidate matrix

Review of existing employee stock compensation matrix and new hire

salary ranges

Clarification to schedule for payment of cash based compensation for

directors

Review of director compensation matrix

Theranos Confidential

4

Visuals: One logo: the theranos logo in the top-left corner, consisting of a green faceted diamond/rhombus emblem with a white inner cross-shaped cutout and gradient shading from light to dark green on the left, followed by the lowercase italic grey wordmark 'theranos' in dark grey (#6D6E71 approx.) and the tagline 'redefining healthcare' in small grey monospaced-style letters beneath it. No photographs, charts, or other graphics.

Slide 7

2010 Goals Recap

Products:

• Launch Theranos Systems 4.0

• Establish volume capacity for millions of tests/month

Commercial:

Cash, Contracts, Market Share from at least 3 of each of:

• Enterprise deals with pharmaceutical companies

• Retail pharmacy deals

• Provider/Health ministry deals

Organization:

• World class products, sales, legal, and finance teams

Theranos Confidential

5

Visuals: One logo at top left: the Theranos mark, a green diamond-like faceted emblem (four-point star with lighter green gradient facets) followed by the italic grey wordmark 'theranos' and the tagline 'redefining healthcare' in small grey italic lowercase beneath it. No photographs, charts, or diagrams.

Slide 8

theranos

redefining healthcare

Products

Device

• 3x & minilab

Cartridge

• Multiplexing 65+ assays

• On board sample collection and processing

Assays

• Aptamers

• 800+ test menu & TPS library

Software

• Decision Support & Services

• Enterprise Pharmaceutical Suite

• Retail Pharmacy Suite

• Provider Suite

Theranos Confidential

6

Visuals: One logo, top-left: the Theranos logo, a green faceted diamond with a white square-cross centre and a grey italic lowercase wordmark 'theranos' with the tagline 'redefining healthcare' in small grey letters beneath. It is a placed raster image of 232 by 63 pixels, not cropped, on a white ground. No charts, photographs, tables or diagrams.

Slide 9

theranos

redefining healthcare

System Integration of New Technologies

Centrifuge

Nucleic Acid Ampl.

Cytometry

Colorimetry

ELISA

Robotics & Machine Vision

Theranos Confidential

7

Visuals: Six photographs of laboratory instruments, each with a black-and-silver palette, shown in oval crops inside light green rounded rectangular panels with grey outlines. Top row, left to right: Centrifuge (a black circular centrifuge rotor with silver posts, a sample holder in the centre, and hex bolts on the base, shot close-up at a slight angle). Nucleic Acid Ampl. (a dark rectangular instrument block with a blue-lit channel on top, a white plastic sample block at left, a green circuit board and tubing, lit with blue light). Cytometry (a ring of white LEDs around a polished steel bowl, with a white plate carrying thin channels and small red-tinted dots in the centre). Bottom row, left to right: Colorimetry (a clear plastic pipette tip descending into a dark background, with a bright white light streak across the lower part). ELISA (a silver pipette tip above an aluminium plate beside a black instrument with a blue label, with other silver probes visible at the top). Robotics & Machine Vision (a black machine frame with threaded lead screws and steel guide rods on a grey background). Each photo is cropped to an oval and sits inside its green panel with the image edges overlapping the panel edges.

Slide 10

theranos / redefining healthcare / Diverse Data Acquisition Across Technologies / Centrifuge / Nucleic Acid Ampl. / Cytometry / Colorimetry / ELISA / Robotics & Machine Vision / Theranos Confidential / 8

Visuals: Six photographs in rounded green cards, plus one green block arrow on the centrifuge card. Centrifuge: two photographs of a clear glass blood tube with a black rubber cap side by side on a white background; the left tube is filled with dark red blood to its full height, and the right tube, after centrifugation, shows a pale yellow plasma layer on top of a dark red cell layer at the bottom; a dark green block arrow with black outline points from left to right between them. Nucleic Acid Amplification: a close-up, boxed, rounded-corner photo of a row of green-lit wells on a black background; four well rings are visible with bright green fluorescent liquid in the centres, lit evenly. Cytometry: an oval-cropped false-colour microscope image on a dark navy background with scattered cells in purple, magenta and orange with bright yellow-white highlights. Colorimetry: an oval-cropped photo of four pipette tips filled with violet-blue liquid on a white background, the liquid getting paler from left to right, with a partly visible fifth tip at the far right edge. ELISA: an oval-cropped photo on black of a vertical tube glowing bright blue with a cyan-white glow at its bottom. Robotics & Machine Vision: an oval-cropped grey-toned image of three pipette tips in a dark grey rack with cyan outlines, containing red liquid in the tips, with a translucent white horizontal band with dashed black edges crossing the upper part of the tips. No charts, tables, logos other than the theranos logo, or icons.

Slide 11

theranos / redefining healthcare / Assay Validation Across Technologies / Centrifuge / Nucleic Acid Ampl. / Cytometry / Count / Log10 (Fluorescence intensity) / Hematocrit, % reported / DNA (ug/ml) / Colorimetry / ELISA / Robotics & Machine Vision / Hematocrit, % target / Predicted Conc (g/dL) / RLU / Nominal Conc (g/dL) / Conc (ng/ml) / Theranos Confidential / 9

Visuals: Six technology panels. Centrifuge: scatter plot titled none, x-axis Hematocrit, % target 0 to 80, y-axis Hematocrit, % reported 0 to 80; blue points at about (0,0), (30,30-32), (50,50-51), (70,68-70); dashed black linear trendline labelled y = 0.9522x + 2.0536, R^2 = 0.9964. Nucleic Acid Ampl.: bar chart, y-axis DNA (ug/ml) 0 to 90 in steps of 10, bars alternating red and blue: Dengue 1 red about 3, Negative Control blue about 4, Dengue 2 red about 3, Negative Control blue about 4, Dengue 3 red about 80 (highlighted tallest), Negative Control blue about 2, Dengue 4 red about 3, Negative Control blue about 3; category labels rotated 45 degrees. Cytometry: pink histogram with two peaks, y-axis Count (no numeric labels visible), x-axis Log10 (Fluorescence intensity) with tick marks, bars in #E8308A-like pink with white outlines; the axis label overflows the card. Colorimetry: scatter of black open circles with fitted line, label y = 1 x + -0.0262 and R^2 = 0.998 (R^2 in red), y-axis Predicted Conc (g/dL), x-axis Nominal Conc (g/dL), no numeric tick labels visible, white plot box. ELISA: blue fitted curve with grey data points, vertical cyan line at about 0.5 and green lines at about 5.00 and 500.00; y-axis RLU with ticks 5000, 20000, 100000; x-axis ticks 0.50, 5.00, 50.00, 500.00 labelled Conc (ng/ml). Robotics & Machine Vision: dense noisy grey-green micro-array texture of horizontal streaks on a white-bordered image, no legend.

Slide 12

Products / Regulatory / FDA / non-significant risk, class I devices / 510(k)s for diagnostic and predictive tests and ultimately, all / chemistries / CMS / CLIA-certification / LDTs / Theranos Confidential / 10

Visuals: Logo only: the theranos corporate mark at top left, a green faceted diamond with a white cross-shaped centre beside the grey italic wordmark 'theranos' and the small grey tagline 'redefining healthcare' below it. No charts, photographs or diagrams.

Slide 13

Operations and Production / Implementation of fully automated lines with comprehensive vision / inspection systems / Alchemist / • Automation of development / CLIA organizations and certifications, GMP (Good Manufacturing / Practices) compliance, and ISO certifications for ongoing regulatory / submissions / Theranos Confidential / 11

Visuals: Visual elements: one logo only. The theranos logo at top-left, 232 by 63 pixels, shows a green faceted diamond mark with a white inner cross pattern, next to a grey italic 'theranos' wordmark and a small grey italic 'redefining healthcare' tagline beneath it. No charts, tables, photographs or diagrams.

Slide 14

Commercial

Theranos businesses:

1.Physician’s office

2.Retail Rx

3.Pharmaceutical

4.Department of Defense, Government

Theranos Confidential

12

Visuals: One logo at top left: the theranos logo, a green faceted diamond mark with lowercase grey italic wordmark 'theranos' and the tagline 'redefining healthcare' beneath it in small grey italic lettering. No photographs, charts, or other graphics.

Slide 15

theranos / redefining healthcare / 2011 Commercial Plan / Q1 / Prepare for retail and physician’s office pilot launch / Regulatory and operations infrastructure in place / Q2 / Initiate retail and physician’s office pilots / Resume pharmaceutical contracts around fully integrated / solution for development acceleration (physical / infrastructure , software decision support, real-time / chemistry) / Q3 / Begin retail and physician’s office rollout / Pharmaceutical deployments / Q4 / Scale rollouts and begin deployments with multiple retail / partners / Theranos Confidential / 13

Visuals: Logo: the theranos corporate logo at top left, consisting of a green faceted diamond mark (four-point diamond with white internal cross-cut lines and a green-to-white gradient) to the left of an italic grey lowercase wordmark 'theranos' with the grey tagline 'redefining healthcare' in small italic letters beneath it. The image is a raster placed at 232 by 63 pixels, not cropped, on white. No photographs, charts, tables or other graphics.

Slide 16

Theranos Confidential / 14 / Commercial: Retail Rx / Walgreens / • $100M inventory pre-purchase / Safeway & Safeway Network / • $55M inventory pre-purchase / • ~$70M inventory pre-purchase / Target, Rite Aid, CVS Minute Clinics, & Walmart

Visuals: One logo, the Theranos wordmark, at top left: a green faceted diamond icon with white cross-shaped highlights and an italic grey 'theranos' wordmark with the tagline 'redefining healthcare' beneath it in small grey type. No photographs, charts, or diagrams.

Slide 17

Commercial: TPS

GSK

Celgene

Centocor

Sanofi-aventis

Astrazeneca

Retail pharmacy contracts with pharmaceutical partners

Theranos Confidential

15

Visuals: Theranos logo at upper left: a green faceted diamond-shaped mark (four-part rhombus with lighter highlights) followed by the lowercase italic grey wordmark 'theranos' and the smaller green-grey tagline 'redefining healthcare' beneath it. No other photographs, charts, or diagrams.

Slide 18

Commercial: Providers / BlueCross BlueShield Association and plans / United / Aetna, Cigna / DoD / IMSS, Pemex / Theranos Confidential / 16

Visuals: Logo: Theranos logo (green faceted diamond mark with italic grey wordmark 'theranos' and the tagline 'redefining healthcare' beneath), placed top-left at x 2.7%, y 3.5%, w 24.2%, h 8.8%, shown as a 232 by 63 pixel raster image with no border or frame. No charts, tables, photographs or other illustrations.

Slide 19

Organization / Our People: Building a World-Class Organization / Re-structured entire organization for scalability and rapid development cycles in preparation for retail launches / 13 team leads in place company wide around which all product and project teams are structured (from development to finance) / Team lead profile: BS, MS from MIT/Stanford, 2-10 years experience / Hiring to continually double headcount (150 people by 3/31/11) / Theranos Confidential / 17

Visuals: One visual element: the Theranos logo at top left (x 2.7%, y 3.5%, 24.2% by 8.8%, placed as a 232 by 63 pixel image). It has a green faceted diamond mark with white inner facets and a shaded green gradient, followed by the grey italic wordmark 'theranos' in a mid-grey (about #5F6368), and the small grey tagline 'redefining healthcare' in a lowercase sans-serif beneath it. No charts, photographs or other graphics appear on the slide.

Slide 20

theranos / redefining healthcare / Legal / Update on Government and Regulatory Affairs / Global Manufacturing Subsidiary & US Production / Intellectual Property & Trademarks / Theranos Confidential / 18

Visuals: Logo: the Theranos logo, a green faceted diamond mark with a white inner cross-like shape, to the right of which is the grey italic lowercase wordmark 'theranos' with the tagline 'redefining healthcare' in small grey italic lowercase beneath it. Bounding box x 2.7%, y 3.5%, w 24.2%, h 8.8% (232 by 63 pixels). No other visuals.

Slide 21

theranos

redefining healthcare

Theranos Intellectual Property Portfolio

Code

Patent Family

Status

Value

704

Pill & patch

Patch issued with narrow claims, other claims still being pursued

Publication blocks other companies from patents

707

Communications

US patent issued; foreign equivalents beginning to issue

Blocking for distributed test systems with wireless communication

711

Calibration

US claims allowed

Protects/blocks on-board calibrators used to update factory calibration

713

Detection of Influenza virus infection

Published, pending

Would protect ideas for assay configurations

725

Multivariate methods

Published, pending

Would protect use of multianalyte trend analysis in disease and therapy management

727

Modular POC systems

Published, pending

Would protect existing immunoassay system (pipette + tips)

732

Integrated health data capture and analysis

PCT filed

Would protect "Theranos Health Shield".; monitor and control ID outbreaks

733

Systems for sample use maximization

In preparation

Would protect the 4.0 System (Image analysis, protocol management, use of centrifuge)

Theranos Confidential

19

Visuals: Logo: raster image (232 by 63 pixels) at top left showing a green faceted diamond-like mark with a grey italic wordmark 'theranos' and small green tagline 'redefining healthcare' beneath. Table: 4 columns and 8 body rows plus header. Header row: Code | Patent Family | Status | Value, white bold text on light green #8AE28C. Row 1: 704 | Pill & patch | Patch issued with narrow claims, other claims still being pursued | Publication blocks other companies from patents. Row 2: 707 | Communications | US patent issued; foreign equivalents beginning to issue | Blocking for distributed test systems with wireless communication. Row 3: 711 | Calibration | US claims allowed | Protects/blocks on-board calibrators used to update factory calibration. Row 4: 713 | Detection of Influenza virus infection | Published, pending | Would protect ideas for assay configurations. Row 5: 725 | Multivariate methods | Published, pending | Would protect use of multianalyte trend analysis in disease and therapy management. Row 6: 727 | Modular POC systems | Published, pending | Would protect existing immunoassay system (pipette + tips). Row 7: 732 | Integrated health data capture and analysis | PCT filed | Would protect "Theranos Health Shield".; monitor and control ID outbreaks. Row 8: 733 | Systems for sample use maximization | In preparation | Would protect the 4.0 System (Image analysis, protocol management, use of centrifuge). Body rows alternate pale teal #E7F3F4 and near-white #F3F9FA. No photographs, charts or icons.

Slide 22

theranos redefining healthcare / Finance / Real Estate Update / Palo Alto: Additional facilities / • 3172 Porter at $2.05 NNN (55k sf) staged lease / • BSL 2/3 labs / • 3201 Hillview / - Utah / Approval of Real Estate Committee / C-2 Financing / Preferred Shares & Share Repurchase / Projected Financial Statements / Theranos Confidential / 20

Visuals: Non-text visuals: one logo image at x 2.7%, y 3.5%, w 24.2%, h 8.8% (232 by 63 pixels). It shows a green faceted diamond-shaped emblem with a white four-point star cut-out in its centre, followed by the italic grey wordmark 'theranos' and the small grey italic line 'redefining healthcare' beneath it. Colours are green gradient (#008851 range, lighter toward the centre) and mid-grey wordmark. No photographs, charts, tables or diagrams. The green footer band is a solid filled rectangle.

Download this deck

The hosted PDF of every library deck is free for readers of the SlideDeck Co newsletter. Join with your email and the viewer and download appear here.

Preparing a results presentation or business update of your own? The SlideDeck Co Standard Deck is a slide library for business reviews, updates and plans.

More Reporting decks

Deck reviews in your inbox.

See what works in real company decks, what we’d change, and get the latest SDC releases.

Expanded slide preview